Norepinephrine: the next therapeutics frontier for Parkinson's disease

Por LeWitt, Peter A
Publicado em 2012

Protection against Parkinson’s disease progression: Clinical experience

Por LeWitt, Peter A., Taylor, Danette C.
Publicado no Neurotherapeutics (2008)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER

Por LeWitt, Peter A., Boroojerdi, Babak, Surmann, Erwin, Poewe, Werner
Publicado em 2012

Nocardia asteroides-induced movement abnormalities in mice: relevance for Parkinson's disease?

Por Loeffler, David A., LeWitt, Peter A., Camp, Dianne M.
Publicado no Mov Disord (2016)

Metabolomic biomarkers as strong correlates of Parkinson disease progression

Por LeWitt, Peter A., Li, Jia, Lu, Mei, Guo, Lining, Auinger, Peggy
Publicado no Neurology (2017)

Clinician Versus Machine: Reliability and Responsiveness of Motor Endpoints in Parkinson's Disease

Por Heldman, Dustin A., Espay, Alberto J., LeWitt, Peter A., Giuffrida, Joseph P.
Publicado em 2014

Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease

Por Camp, Dianne M, Loeffler, David A, Farrah, Diane M, Borneman, Jade N, LeWitt, Peter A
Publicado em 2009

Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress

Por Loeffler, David A., Klaver, Andrea C., Coffey, Mary P., Aasly, Jan O., LeWitt, Peter A.
Publicado no Front Aging Neurosci (2016)

Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson’s Disease-Associated LRRK2 Gene Mutations

Por Loeffler, David A., Klaver, Andrea C., Coffey, Mary P., Aasly, Jan O., LeWitt, Peter A.
Publicado no Front Aging Neurosci (2017)

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis

Por LeWitt, Peter A., Poewe, Werner, Elmer, Lawrence W., Asgharnejad, Mahnaz, Boroojerdi, Babak, Grieger, Frank, Bauer, Lars
Publicado no Clin Neuropharmacol (2016)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm

Por Truong, Daniel D., Gollomp, Stephen M., Jankovic, Joseph, LeWitt, Peter A., Marx, Michael, Hanschmann, Angelika, Fernandez, Hubert H.
Publicado em 2013

Multimodal Imaging in a Patient with Hemidystonia Responsive to GPi Deep Brain Stimulation

Por Sidiropoulos, Christos, Bowyer, Susan M., Zillgitt, Andrew, LeWitt, Peter A., Bagher-Ebadian, Hassan, Davoodi-Bojd, Esmaeil, Schwalb, Jason M., Rammo, Richard, Air, Ellen, Soltanian-Zadeh, Hamid
Publicado no Case Rep Neurol Med (2017)

Urate predicts rate of clinical decline in Parkinson disease

Por Ascherio, Alberto, LeWitt, Peter A., Xu, Kui, Eberly, Shirley, Watts, Arthur, Matson, Wayne R., Marras, Connie, Kieburtz, Karl, Rudolph, Alice, Bogdanov, Mikhail B., Schwid, Steven R., Tennis, Marsha, Tanner, Caroline M., Beal, M. Flint, Lang, Anthony E., Oakes, David, Fahn, Stanley, Shoulson, Ira, Schwarzschild, Michael A.
Publicado em 2009

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease

Por Niethammer, Martin, Tang, Chris C., LeWitt, Peter A., Rezai, Ali R., Leehey, Maureen A., Ojemann, Steven G., Flaherty, Alice W., Eskandar, Emad N., Kostyk, Sandra K., Sarkar, Atom, Siddiqui, Mustafa S., Tatter, Stephen B., Schwalb, Jason M., Poston, Kathleen L., Henderson, Jaimie M., Kurlan, Roger M., Richard, Irene H., Sapan, Christine V., Eidelberg, David, During, Matthew J., Kaplitt, Michael G., Feigin, Andrew
Publicado no JCI Insight (2017)